Supreme Court rules for Teva in over multiple sclerosis drug patent

Teva plant is seen in JerusalemWASHINGTON (Reuters) – The U.S. Supreme Court on Tuesday ruled for Teva Pharmaceutical Industries Ltd in its fight with generic drug manufacturers over patent protections for Copaxone, its top-selling multiple sclerosis drug, by sending the case back to a lower court for further review. On a 7-2 vote, the justices said that the U.S. Court of Appeals for the Federal Circuit had not used the correct approach in analyzing whether the patent in question, due to expire in September 2015, was valid. (Reporting by Lawrence Hurley; Editing by Will Dunham)

Go to Source

Economic impact of Ebola less severe than first thought: World Bank

Health workers push a wheeled stretcher holding a newly admitted Ebola patient, 16-year-old Amadou, in to the Save the Children Kerry town Ebola treatment centre outside Freetown, Sierra LeoneThe economic impact of Ebola on African economies in 2015 will be less severe than previously thought, the World Bank said in a report on Tuesday, causing just a fraction of the more than $25 billion in losses first expected. The GDP impact on countries beyond the three directly affected — Guinea, Liberia and Sierra Leone — is now estimated at $500 million as governments make progress in fighting the disease. The first Ebola outbreak in West Africa began 13 months ago when a Guinean toddler became infected with the haemorrhagic fever. "I am very encouraged to see Ebola transmission rates slowing markedly in Guinea, Liberia, and Sierra Leone, and that other potential outbreaks have been averted because of swift action by other West African governments," Jim Yong Kim, President of the World Bank Group, said in the report.

Go to Source

1 21 22 23 24 25 59